- Home
- GNS vs BCTX Comparison
GNS vs BCTX Comparison
Compare GNS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNS | BCTX |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | Singapore | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 28.8M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GNS | BCTX |
|---|---|---|
| Price | $0.45 | $4.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | ★ 917.9K | 161.2K |
| Earning Date | 03-09-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $156.26 | N/A |
| Revenue Next Year | $35.38 | $380.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.61 |
| 52 Week High | $1.92 | $14.68 |
Technical Indicators
Market Signals| Indicator | GNS | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 56.58 |
| Support Level | $0.36 | $3.66 |
| Resistance Level | $0.48 | $5.16 |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 88.53 | 91.76 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.